(MENAFN- GlobeNewsWire - Nasdaq) New study published in Nature Communications paves the way for next-generation pandemic preparedness, demonstrating safety and immunogenicity of adjuvanted intranasal bird flu vaccine

ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- BlueWillow Biologics, Inc., a clinical-stage biotech company pioneering the future of intranasal vaccines, today announced results from a peer-reviewed Nature Communications study demonstrating that its intranasal, adjuvanted H5N1 influenza vaccine candidate successfully primed broad immune responses across multiple avian flu strains. The randomized, controlled Phase I clinical trial, conducted by researchers at University of Maryland School of Medicine), demonstrated BlueWillow's NanoVax^® W805EC adjuvanted A/H5 vaccine effectively primed broad immune responses in trial patients with a strong safety profile against diverse strains of bird flu, highlighting its potential as a next-generation approach for pandemic preparedness.

“The continued spread of H5N1 on European farms and human fatality in Louisiana earlier this year highlights the urgent need for effective preventive measures,” said Chad Costley, MD, MBA, CEO of BlueWillow.“The results from this clinical trial show that our NanoVax^® W805EC adjuvanted A/H5 vaccine is capable of safely inducing strong and broad immunogenicity with the promise of preventing both disease symptoms and contagiousness.”

In the Phase I clinical trial, 40 healthy adults were randomized to receive low, medium and high A/H5 vaccine doses combined with BlueWillow's proprietary, intranasal, oil-in-water W805EC emulsion adjuvant, high-dose antigen alone or placebo. Adjuvanted intranasal vaccination was safe and well-tolerated in all subjects. Only the subjects who received the intranasal adjuvanted vaccines showed broad immune systemic priming, which was revealed by a single dose of a currently licensed intramuscular H5 vaccine. Importantly, the NanoVax^® W805EC adjuvanted vaccination also elicited mucosal, cellular and systemic immune responses on its own, something that has not been previously demonstrated in clinical trials of other recombinant H5 mucosal flu vaccine candidates.

BlueWillow's NanoVax^® W805EC adjuvanted vaccine also demonstrated significant cross-clade immune system priming against multiple H5N1 strains, signifying that the vaccine stimulates the immune system to recognize variations of the virus which is critical to protection as the flu virus mutates over time. The study also indicates a potential antigen dose-sparing benefit of the NanoVax^® W805EC adjuvant. Antigen dose-sparing is important to lowering the cost and increasing the tolerability and safety of vaccination.

“The spread of H5N1 influenza in animals with spillover into human populations globally highlights the critical need for effective countermeasures to protect our communities from this and other pathogens with pandemic potential,” said Justin Ortiz, MD, MS, lead author on the study and professor at the University of Maryland School of Medicine.“This trial shows that this intranasal, shelf-stable H5N1 vaccine could play a major role in pandemic preparedness, offering a practical and scalable way to help protect people from evolving strains of the virus.”

BlueWillow's NanoVax^® W805EC adjuvant, previously named NE01, is the most advanced intranasal adjuvant in development and warrants further investigation as a platform technology for advancing mucosal vaccination against a range of respiratory pathogens.

For more information about BlueWillow Biologics and its intranasal platform technology, please visit

About BlueWillow

Based in Ann Arbor, Michigan, BlueWillow Biologics, Inc.

Media Contact
Kristin Rose Jutras
TellMed Strategies
908.947.0500 x719
...

MENAFN06112025004107003653ID1110303975